Virological response and resistance mutations to NS3/4A inhibitors in hepatitis C virus-human immunodeficiency virus coinfection

Figure 1 Antiretroviral treatment regimens at initiation of triple anti-hepatitis C virus therapy (n = 41). PI: Protease inhibitor (atazanavir, darunavir, lopinavir, ritonavir boost); NRTI: Nucleoside analogue reverse transcriptase inhibitor (tenofovir, emtricitabine, abacavir, lamivudine); NNRTI: Non-nucleoside analogue reverse transcriptase inhibitor (efavirenz, etravirine); INSTI: Integrase strand transfer inhibitor (raltegravir).